PYXS News

Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness (IFIT) and drug developer AEON Biopharma (AEON). New filers continued to flood the pipeline, with 22 IPOs and 12 SPACs submitting initial filings. Canada-listed...read more

Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, raised $168 million by offering 10.5 million shares at $16, the high end of the range of $14 to $16. The company offered 1.0 million more shares than anticipated. It originally planned to offer 8.3 million shares before increasing the offering to 9.5 million shares on Thursday. ...read more

Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, raised the proposed deal size for its upcoming IPO on Thursday. The Cambridge, MA-based company now plans to raise $143 million by offering 9.5 million shares at a price range of $14 to $16. The company had previously filed to offer 8.3 million shares at the same range. At the...read more

Pyxis Oncology, a preclinical biotech developing antibody therapies for solid and hematologic tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Pyxis Oncology would command a fully diluted market value of $493 million. ...read more